Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
How GLP3Planner Calculates Drug Levels
referenceTechnical overview of the pharmacokinetic model behind GLP3Planner. Covers the one-compartment model with first-order absorption, the Bateman equation, drug parameters sourced from clinical trials, multi-dose superposition and steady state, the reconstitution math (BAC water to syringe units), and the standard per-compound titration ladders.
Retatrutide Half-Life & Pharmacokinetics: 6-Day Decay Curve
articleThe definitive guide to retatrutide (reta) pharmacokinetics: approximately 6 days half-life per NEJM Phase 2 data, 30-day full clearance, and 4-5 week steady state per dose level. Includes half-life comparison to tirzepatide and semaglutide, dosing implications, and FAQ.
Retatrutide Steady State Chart: Week-by-Week Accumulation
articleHow retatrutide drug levels build week over week toward steady-state plateau. A model-derived accumulation chart per dose level, why the 4-week titration hold matches the pharmacokinetics, and the practical implications for evaluating each dose.